Related references
Note: Only part of the references are listed.GPC3-targeted immunoPET imaging of hepatocellular carcinomas
Shuxian An et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2022)
Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA
Ghassan K. Abou-Alfa et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma
Ann-Lii Cheng et al.
JOURNAL OF HEPATOLOGY (2022)
Glypican-3-Targeted 227Th α-Therapy Reduces Tumor Burden in an Orthotopic Xenograft Murine Model of Hepatocellular Carcinoma
Kevin P. Labadie et al.
JOURNAL OF NUCLEAR MEDICINE (2022)
Smart NIR-II croconaine dye-peptide for enhanced photo-sonotheranostics of hepatocellular carcinoma
Shuang Li et al.
THERANOSTICS (2022)
Multipoint Costriking Nanodevice Eliminates Primary Tumor Cells and Associated-Circulating Tumor Cells for Enhancing Metastasis Inhibition and Therapeutic Effect on HCC
Weiwei Mu et al.
ADVANCED SCIENCE (2022)
Glypican-3: A Novel and Promising Target for the Treatment of Hepatocellular Carcinoma
Xiufeng Zheng et al.
FRONTIERS IN ONCOLOGY (2022)
Nanomedicine in Hepatocellular Carcinoma: A New Frontier in Targeted Cancer Treatment
Anita Bakrania et al.
PHARMACEUTICS (2022)
BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update
Maria Reig et al.
JOURNAL OF HEPATOLOGY (2022)
pH-Responsive Nanocarriers in Cancer Therapy
Nour M. AlSawaftah et al.
POLYMERS (2022)
Circulating biomarkers in the diagnosis and management of hepatocellular carcinoma
Philip Johnson et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2022)
Durvalumab plus tremelimumab in unresectable hepatocellular carcinoma
Masatoshi Kudo
HEPATOBILIARY SURGERY AND NUTRITION (2022)
Research on the Construction of Bispecific-Targeted Sustained-Release Drug-Delivery Microspheres and Their Function in Treatment of Hepatocellular Carcinoma
Zi-Li Huang et al.
ACS OMEGA (2022)
The Emerging Roles of Exosomes in the Chemoresistance of Hepatocellular Carcinoma
Jie Zhang et al.
CURRENT MEDICINAL CHEMISTRY (2021)
Addressing the worldwide hepatocellular carcinoma: epidemiology, prevention and management
Hrishikesh Samant et al.
JOURNAL OF GASTROINTESTINAL ONCOLOGY (2021)
Proton beam radiotherapy vs. radiofrequency ablation for recurrent hepatocellular carcinoma: A randomized phase III trial
Tae Hyun Kim et al.
JOURNAL OF HEPATOLOGY (2021)
Hyaluronic acid and albumin based nanoparticles for drug delivery
Can Lei et al.
JOURNAL OF CONTROLLED RELEASE (2021)
Glypican-3-Targeted Alpha Particle Therapy for Hepatocellular Carcinoma
Meghan M. Bell et al.
MOLECULES (2021)
Nivolumab plus Ipilimumab for patients with hepatocellular carcinoma previously treated with Sorafenib
Josephine Tsang et al.
EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY (2021)
Biodegradable Polymeric Nanoparticles for Drug Delivery to Solid Tumors
Agnese Gagliardi et al.
FRONTIERS IN PHARMACOLOGY (2021)
Serum Albumin Nanoparticles: Problems and Prospects
Viktoria Hornok
POLYMERS (2021)
DT389-YP7, a Recombinant Immunotoxin against Glypican-3 That Inhibits Hepatocellular Cancer Cells: An In Vitro Study
Hamid Hashemi Yeganeh et al.
TOXINS (2021)
Phase I studies of peptide vaccine cocktails derived from GPC3, WDRPUH and NEIL3 for advanced hepatocellular carcinoma
Masafumi Ikeda et al.
IMMUNOTHERAPY (2021)
Chitosan Nanoparticles at the Biological Interface: Implications for Drug Delivery
Noorjahan Aibani et al.
PHARMACEUTICS (2021)
Emerging Nano-Based Strategies Against Drug Resistance in Tumor Chemotherapy
Lei Cao et al.
FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY (2021)
Hepatocellular Carcinoma: An Overview of the Changing Landscape of Treatment Options
Andreas Koulouris et al.
JOURNAL OF HEPATOCELLULAR CARCINOMA (2021)
Phase I trial of fourth-generation chimeric antigen receptor T-cells targeting glypican-3 for advanced hepatocellular carcinoma.
Weijia Fang et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Nanomaterials for cancer therapy: current progress and perspectives
Zhe Cheng et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)
A Humanized Anti-GPC3 Antibody for Immuno-Positron Emission Tomography Imaging of Orthotopic Mouse Model of Patient-Derived Hepatocellular Carcinoma Xenografts
Arutselvan Natarajan et al.
CANCERS (2021)
Hepatocellular carcinoma: a clinical and pathological overview
Salvatore Lorenzo Renne et al.
PATHOLOGICA (2021)
Nanoparticles for Cancer Therapy: Current Progress and Challenges
Shreelaxmi Gavas et al.
NANOSCALE RESEARCH LETTERS (2021)
Hybridoma technology; advancements, clinical significance, and future aspects
Sanchita Mitra et al.
JOURNAL OF GENETIC ENGINEERING AND BIOTECHNOLOGY (2021)
Engineered Anti-GPC3 Immunotoxin, HN3-ABD-T20, Produces Regression in Mouse Liver Cancer Xenografts Through Prolonged Serum Retention
Bryan D. Fleming et al.
HEPATOLOGY (2020)
Towards the overcoming of anticancer drug resistance mediated by p53 mutations
Xin Cao et al.
DRUG RESISTANCE UPDATES (2020)
Phospholipids and cholesterol: Inducers of cancer multidrug resistance and therapeutic targets
Joanna Kopecka et al.
DRUG RESISTANCE UPDATES (2020)
Targeting the ubiquitin-proteasome pathway to overcome anti-cancer drug resistance
Silpa Narayanan et al.
DRUG RESISTANCE UPDATES (2020)
Advances in molecular classification and precision oncology in hepatocellular carcinoma
Sandra Rebouissou et al.
JOURNAL OF HEPATOLOGY (2020)
Delivery of triptolide with reduction-sensitive polymer nanoparticles for liver cancer therapy on patient-derived xenografts models
Mengxue He et al.
CHINESE CHEMICAL LETTERS (2020)
Long non-coding RNAs as a determinant of cancer drug resistance: Towards the overcoming of chemoresistance via modulation of lncRNAs
Wenxiao Jiang et al.
DRUG RESISTANCE UPDATES (2020)
Glypican-3-Specific CAR T Cells Coexpressing IL15 and IL21 Have Superior Expansion and Antitumor Activity against Hepatocellular Carcinoma
Sai Arun Batra et al.
CANCER IMMUNOLOGY RESEARCH (2020)
Preclinical PET imaging of bispecific antibody ERY974 targeting CD3 and glypican 3 reveals that tumor uptake correlates to T cell infiltrate
Stijn J. H. Waaijer et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
Richard S. Finn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Glucose Metabolism and Oxidative Stress in Hepatocellular Carcinoma: Role and Possible Implications in Novel Therapeutic Strategies
Monica Mossenta et al.
CANCERS (2020)
Stimuli-Responsive Polymeric Nanocarriers for Drug Delivery, Imaging, and Theragnosis
Sabya Sachi Das et al.
POLYMERS (2020)
Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib The CheckMate 040 Randomized Clinical Trial
Thomas Yau et al.
JAMA ONCOLOGY (2020)
Nanoparticle-Based Drug Delivery in Cancer Therapy and Its Role in Overcoming Drug Resistance
Yihan Yao et al.
FRONTIERS IN MOLECULAR BIOSCIENCES (2020)
Transferrin receptor regulates malignancies and the stemness of hepatocellular carcinoma-derived cancer stem-like cells by affecting iron accumulation
Chong Xiao et al.
PLOS ONE (2020)
hGC33-Modified and Sorafenib-Loaded Nanoparticles have a Synergistic Anti-Hepatoma Effect by Inhibiting Wnt Signaling Pathway
Jing Shen et al.
NANOSCALE RESEARCH LETTERS (2020)
Glypican-3: A New Target for Diagnosis and Treatment of Hepatocellular Carcinoma
Meng Guo et al.
JOURNAL OF CANCER (2020)
Transferrin receptor 1 overexpression is associated with tumour de-differentiation and acts as a potential prognostic indicator of hepatocellular carcinoma
Makiko Adachi et al.
HISTOPATHOLOGY (2019)
Transferrin-Conjugated Polymeric Nanoparticle for Receptor-Mediated Delivery of Doxorubicin in Doxorubicin-Resistant Breast Cancer Cells
Zar Chi Soe et al.
PHARMACEUTICS (2019)
Hepatocellular Carcinoma
Augusto Villanueva
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Expression of Prostate-Specific Membrane Antigen in Tumor-Associated Vasculature Predicts Poor Prognosis in Hepatocellular Carcinoma
Dian Jiao et al.
CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY (2019)
Next-Generation Cancer Immunotherapy Targeting Glypican-3
Yasuhiro Shimizu et al.
FRONTIERS IN ONCOLOGY (2019)
Promoting Early Diagnosis and Precise Therapy of Hepatocellular Carcinoma by Glypican-3-Targeted Synergistic Chemo-Photothermal Theranostics
Weiwei Mu et al.
ACS APPLIED MATERIALS & INTERFACES (2019)
Molecular and histological correlations in liver cancer
Julien Calderaro et al.
JOURNAL OF HEPATOLOGY (2019)
Current trends and challenges in cancer management and therapy using designer nanomaterials
P. N. Navya et al.
NANO CONVERGENCE (2019)
In Vitro Performance of Published Glypican 3-Targeting Peptides TJ12P1 and L5 Indicates Lack of Specificity and Potency
Rose M. Berman et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2019)
The multi-factorial nature of clinical multidrug resistance in cancer
Yehuda G. Assaraf et al.
DRUG RESISTANCE UPDATES (2019)
Glypican 3-Targeted Therapy in Hepatocellular Carcinoma
Takahiro Nishida et al.
CANCERS (2019)
Synthesis, Bioapplications, and Toxicity Evaluation of Chitosan-Based Nanoparticles
Balsam R. Rizeq et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Models for Understanding Resistance to Chemotherapy in Liver Cancer
Jose J. G. Marin et al.
CANCERS (2019)
Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Andrew X. Zhu et al.
LANCET ONCOLOGY (2019)
Epigenetics of hepatocellular carcinoma
Tan Boon Toh et al.
CLINICAL AND TRANSLATIONAL MEDICINE (2019)
Product review on the Anti-PD-L1 antibody atezolizumab
Neil J. Shah et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2018)
SR-B1: A Unique Multifunctional Receptor for Cholesterol Influx and Efflux
Wen-Jun Shen et al.
ANNUAL REVIEW OF PHYSIOLOGY, VOL 80 (2018)
Resistance a major hindrance to chemotherapy in hepatocellular carcinoma: an insight
K. Lohitesh et al.
CANCER CELL INTERNATIONAL (2018)
Anti-GPC3 antibody-modified sorafenib-loaded nanoparticles significantly inhibited HepG2 hepatocellular carcinoma
Xiaolong Tang et al.
DRUG DELIVERY (2018)
Redundant angiogenic signaling and tumor drug resistance
Rajesh N. Gacche et al.
DRUG RESISTANCE UPDATES (2018)
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Peter R. Galle et al.
JOURNAL OF HEPATOLOGY (2018)
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
Masatoshi Kudo et al.
LANCET (2018)
Enhanced delivery of sorafenib with anti-GPC3 antibody-conjugated TPGS-b-PCL/Pluronic P123 polymeric nanoparticles for targeted therapy of hepatocellular carcinoma
Huaiyong Gan et al.
MATERIALS SCIENCE AND ENGINEERING C-MATERIALS FOR BIOLOGICAL APPLICATIONS (2018)
Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
G. K. Abou-Alfa et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Drug-eluting beads transarterial chemoembolization for hepatocellular carcinoma: Current state of the art
Antonio Facciorusso
WORLD JOURNAL OF GASTROENTEROLOGY (2018)
Advances in targeting the folate receptor in the treatment/imaging of cancers
Marcos Fernandez et al.
CHEMICAL SCIENCE (2018)
Review on nanoparticles and nanostructured materials: history, sources, toxicity and regulations
Jaison Jeevanandam et al.
BEILSTEIN JOURNAL OF NANOTECHNOLOGY (2018)
The Roles of Protein Tyrosine Phosphatases in Hepatocellular Carcinoma
Yide Huang et al.
CANCERS (2018)
Detecting GPC3-Expressing Hepatocellular Carcinoma with L5 Peptide-Guided Pretargeting Approach: In Vitro and In Vivo MR Imaging Experiments
Weiyue Li et al.
CONTRAST MEDIA & MOLECULAR IMAGING (2018)
Molecular therapies and precision medicine for hepatocellular carcinoma
Josep M. Llovet et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Modulating ROS to overcome multidrug resistance in cancer
Qingbin Cui et al.
DRUG RESISTANCE UPDATES (2018)
Advances in genomic hepatocellular carcinoma research
Weitai Huang et al.
GIGASCIENCE (2018)
Impact of antitumor activity on survival outcomes, and nonconventional benefit, with nivolumab (NIVO) in patients with advanced hepatocellular carcinoma (aHCC): Subanalyses of CheckMate-040.
Anthony B. El-Khoueiry et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
KEYNOTE-224: Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib.
Andrew X. Zhu et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Nanotechnology Strategies To Advance Outcomes in Clinical Cancer Care
Christopher M. Hartshorn et al.
ACS NANO (2018)
Identification of a Glypican-3-Binding Peptide for In Vivo Non-Invasive Human Hepatocellular Carcinoma Detection
Zainen Qin et al.
MACROMOLECULAR BIOSCIENCE (2017)
Digitoxin synergizes with sorafenib to inhibit hepatocelluar carcinoma cell growth without inhibiting cell migration
Yijun Xia et al.
MOLECULAR MEDICINE REPORTS (2017)
Construction of an immunotoxin, HN3-mPE24, targeting glypican-3 for liver cancer therapy
Chunguang Wang et al.
ONCOTARGET (2017)
Targeted cancer therapy through antibody fragments-decorated nanomedicines
Abbas Alibakhshi et al.
JOURNAL OF CONTROLLED RELEASE (2017)
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
Jordi Bruix et al.
LANCET (2017)
Human Hepatocarcinoma Cell Targeting by Glypican-3 Ligand Peptide Functionalized Silica Nanoparticles: Implications for Ultrasound Molecular Imaging
Marco Di Paola et al.
LANGMUIR (2017)
Cancer drug delivery in the nano era: An overview and perspectives (Review)
Zhen Li et al.
ONCOLOGY REPORTS (2017)
An anti-glypican 3/CD3 bispecific T cell-redirecting antibody for treatment of solid tumors
Takahiro Ishiguro et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
The Roles of Carcinoembryonic Antigen in Liver Metastasis and Therapeutic Approaches
Joo Han Lee et al.
GASTROENTEROLOGY RESEARCH AND PRACTICE (2017)
Overexpression of CD147 is associated with poor prognosis, tumor cell migration and ERK signaling pathway activation in hepatocellular carcinoma
Wenjing Xiao et al.
EXPERIMENTAL AND THERAPEUTIC MEDICINE (2017)
Anti-GPEC3-CAR T Cells Suppress the Growth of Tumor Cells in Patient-Derived Xenogratfts of Hepatocelluar Carcinoma
Zhiwu Jiang et al.
FRONTIERS IN IMMUNOLOGY (2017)
A phase I study of anti-GPC3 chimeric antigen receptor modified T cells (GPC3 CAR-T) in Chinese patients with refractory or relapsed GPC3+hepatocellular carcinoma (r/r GPC3+HCC).
Bo Zhai et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Cancer nanomedicine: a review of recent success in drug delivery
Stephanie Tran et al.
CLINICAL AND TRANSLATIONAL MEDICINE (2017)
The use of 5-fluorouracil-loaded nanobubbles combined with low-frequency ultrasound to treat hepatocellular carcinoma in nude mice
Qiaoya Li et al.
EUROPEAN JOURNAL OF MEDICAL RESEARCH (2017)
pH-sensitive polymeric nanoparticles for co-delivery of doxorubicin and curcumin to treat cancer via enhanced pro-apoptotic and anti-angiogenic activities
Jinming Zhang et al.
ACTA BIOMATERIALIA (2017)
Hepatic stellate cells limit hepatocellular carcinoma progression through the orphan receptor endosialin
Carolin Mogler et al.
EMBO MOLECULAR MEDICINE (2017)
Elevated Preoperative Serum CEA Level Is Associated with Poor Prognosis in Patients with Hepatocellular Carcinoma Through the Epithelial-Mesenchymal Transition
Masato Yoshikawa et al.
ANTICANCER RESEARCH (2017)
Targeted nanomedicine for cancer therapeutics: Towards precision medicine overcoming drug resistance
Maya Bar-Zeev et al.
DRUG RESISTANCE UPDATES (2017)
Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC)
Ghassan K. Abou-Alfa et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2017)
Polymeric nanoparticles: the future of nanomedicine
Brittany L. Banik et al.
WILEY INTERDISCIPLINARY REVIEWS-NANOMEDICINE AND NANOBIOTECHNOLOGY (2016)
Old drugs, novel ways out: Drug resistance toward cytotoxic chemotherapeutics
Ruud H. Wijdeven et al.
DRUG RESISTANCE UPDATES (2016)
Lysosomes as mediators of drug resistance in cancer
Benny Zhitomirsky et al.
DRUG RESISTANCE UPDATES (2016)
Overcoming ABC transporter-mediated multidrug resistance: Molecular mechanisms and novel therapeutic drug strategies
Wen Li et al.
DRUG RESISTANCE UPDATES (2016)
Randomized phase II placebo controlled study of codrituzumab in previously treated patients with advanced hepatocellular carcinoma
Ghassan K. Abou-Alfa et al.
JOURNAL OF HEPATOLOGY (2016)
Modeling of Hepatocytes Proliferation Isolated from Proximal and Distal Zones from Human Hepatocellular Carcinoma Lesion
Mauro Montalbano et al.
PLOS ONE (2016)
Doxorubicin-Loaded Nanobubbles Combined with Extracorporeal Shock Waves: Basis for a New Drug Delivery Tool in Anaplastic Thyroid Cancer
Francesca Marano et al.
THYROID (2016)
Phase II study of the GPC3-derived peptide vaccine as an adjuvant therapy for hepatocellular carcinoma patients
Yu Sawada et al.
ONCOIMMUNOLOGY (2016)
Hepatocellular carcinoma
Josep M. Llovet et al.
NATURE REVIEWS DISEASE PRIMERS (2016)
Humanization of high-affinity antibodies targeting glypican-3 in hepatocellular carcinoma
Yi-Fan Zhang et al.
SCIENTIFIC REPORTS (2016)
Global Epidemiology of Hepatocellular Carcinoma An Emphasis on Demographic and Regional Variability
Katherine A. McGlynn et al.
CLINICS IN LIVER DISEASE (2015)
Microenvironment acidity as a major determinant of tumor chemoresistance: Proton pump inhibitors (PPIs) as a novel therapeutic approach
Sophie Taylor et al.
DRUG RESISTANCE UPDATES (2015)
Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy
Edgar Perez-Herrero et al.
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS (2015)
CD147 reprograms fatty acid metabolism in hepatocellular carcinoma cells through Alct/mTOR/SRESP1c and P38/PPARα pathways
Jibin Li et al.
JOURNAL OF HEPATOLOGY (2015)
Principles of nanoparticle design for overcoming biological barriers to drug delivery
Elvin Blanco et al.
NATURE BIOTECHNOLOGY (2015)
Robo1 promotes angiogenesis in hepatocellular carcinoma through the Rho family of guanosine triphosphatases' signaling pathway
Jian-Yang Ao et al.
TUMOR BIOLOGY (2015)
Multifunctional HER2-Antibody Conjugated Polymeric Nanocarrier-Based Drug Delivery System for Multi-Drug-Resistant Breast Cancer Therapy
Raju Vivek et al.
ACS APPLIED MATERIALS & INTERFACES (2014)
Engineered Nanoparticles for Drug Delivery in Cancer Therapy
Tianmeng Sun et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2014)
Cabozantinib Suppresses Tumor Growth and Metastasis in Hepatocellular Carcinoma by a Dual Blockade of VEGFR2 and MET
Qingfeng Xiang et al.
CLINICAL CANCER RESEARCH (2014)
The folate receptor as a rational therapeutic target for personalized cancer treatment
Yehuda G. Assaraf et al.
DRUG RESISTANCE UPDATES (2014)
The Correlation of Expression Levels of HIF-1 and HIF-2 in Hepatocellular Carcinoma with Capsular Invasion, Portal Vein Tumor Thrombi and Patients Clinical Outcome
Sheng-Li Yang et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2014)
Glypican-3 binds to Frizzled and plays a direct role in the stimulation of canonical Wnt signaling
Mariana Capurro et al.
JOURNAL OF CELL SCIENCE (2014)
EPR: Evidence and fallacy
Joseph W. Nichols et al.
JOURNAL OF CONTROLLED RELEASE (2014)
Positive glypican-3 expression in early hepatocellular carcinoma predicts recurrence after hepatectomy
I-Pei Chen et al.
JOURNAL OF GASTROENTEROLOGY (2014)
CD147 promotes reprogramming of glucose metabolism and cell proliferation in HCC cells by inhibiting the p53-dependent signaling pathway
Qichao Huang et al.
JOURNAL OF HEPATOLOGY (2014)
Lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage
Yuji Yamamoto et al.
VASCULAR CELL (2014)
Rationally designed nanovehicles to overcome cancer chemoresistance
Yoav D. Livney et al.
ADVANCED DRUG DELIVERY REVIEWS (2013)
Expression pattern of tumour-associated antigens in hepatocellular carcinoma: association with immune infiltration and disease progression
J. Liang et al.
BRITISH JOURNAL OF CANCER (2013)
First-in-Man Phase I Study of GC33, a Novel Recombinant Humanized Antibody Against Glypican-3, in Patients with Advanced Hepatocellular Carcinoma
Andrew X. Zhu et al.
CLINICAL CANCER RESEARCH (2013)
Potential and problems in ultrasound-responsive drug delivery systems
Ying-Zheng Zhao et al.
INTERNATIONAL JOURNAL OF NANOMEDICINE (2013)
Expression of Asialoglycoprotein Receptor 1 in Human Hepatocellular Carcinoma
Bin Shi et al.
JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY (2013)
Therapeutically targeting glypican-3 via a conformation-specific single-domain antibody in hepatocellular carcinoma
Mingqian Feng et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Liposome: classification, preparation, and applications
Abolfazl Akbarzadeh et al.
NANOSCALE RESEARCH LETTERS (2013)
Phase I Trial of a Glypican-3-Derived Peptide Vaccine for Advanced Hepatocellular Carcinoma: Immunologic Evidence and Potential for Improving Overall Survival
Yu Sawada et al.
CLINICAL CANCER RESEARCH (2012)
PLGA-based nanoparticles: An overview of biomedical applications
Fabienne Danhier et al.
JOURNAL OF CONTROLLED RELEASE (2012)
High-affinity monoclonal antibodies to cell surface tumor antigen glypican-3 generated through a combination of peptide immunization and flow cytometry screening
Yen Phung et al.
MABS (2012)
Glypican-3 expression and its relationship with recurrence of HCC after liver transplantation
Yu-Liang Wang et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2012)
A glypican-3-derived peptide vaccine against hepatocellular carcinoma
Yu Sawada et al.
ONCOIMMUNOLOGY (2012)
Glypican-3: A new target for cancer immunotherapy
Mitchell Ho et al.
EUROPEAN JOURNAL OF CANCER (2011)
Targeting of hepatocellular carcinoma with glypican-3-targeting peptide ligand
You La Lee et al.
JOURNAL OF PEPTIDE SCIENCE (2011)
ULTRASOUND-TRIGGERED DRUG RELEASE AND ENHANCED ANTICANCER EFFECT OF DOXORUBICIN-LOADED POLY(D,L-LACTIDE-CO-GLYCOLIDE)-METHOXY-POLY(ETHYLENE GLYCOL) NANODROPLETS
Lina Du et al.
ULTRASOUND IN MEDICINE AND BIOLOGY (2011)
Immunostaining of PD-1/PD-Ls in liver tissues of patients with hepatitis and hepatocellular carcinoma
Bao-Ju Wang et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2011)
The Angiogenic Growth Factor and Biomarker Midkine Is a Tumor-Shared Antigen
Jerome Kerzerho et al.
JOURNAL OF IMMUNOLOGY (2010)
Diagnostic value of glypican-3 in serum and liver for primary hepatocellular carcinoma
Hui Liu et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2010)
Glypican-3 expression is correlated with poor prognosis in hepatocellular carcinoma
Hirofumi Shirakawa et al.
CANCER SCIENCE (2009)
Nanoparticle-based targeted drug delivery
Rajesh Singh et al.
EXPERIMENTAL AND MOLECULAR PATHOLOGY (2009)
MUC1, MUC2 and MUC5AC expression in hepatocellular carcinoma with cardiac metastasis
Yu-Sheng Lin et al.
MOLECULAR MEDICINE REPORTS (2009)
Glypican 3 expression in human nonneoplastic, preneoplastic, and neoplastic tissues: A tissue microarray analysis of 4,387 tissue samples
Daniel Baumhoer et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2008)
Endosialin (Tem1) is a marker of tumor-associated myofibroblasts and tumor vessel-associated mural cells
Sven Christian et al.
AMERICAN JOURNAL OF PATHOLOGY (2008)
Anti-Glypican 3 Antibody as a Potential Antitumor Agent for Human Liver Cancer
Takahiro Ishiguro et al.
CANCER RESEARCH (2008)
EpCAM and α-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma
Taro Yamashita et al.
CANCER RESEARCH (2008)
The role of glypican-3 in the regulation of body size and cancer
Jorge Filmus et al.
CELL CYCLE (2008)
Glypican-3 expression in benign liver tissue with active hepatitis C: implications for the diagnosis of hepatocellular carcinoma
Hala M. Abdul-Al et al.
HUMAN PATHOLOGY (2008)
Factors affecting the clearance and biodistribution of polymeric nanoparticles
Frank Alexis et al.
MOLECULAR PHARMACEUTICS (2008)
Sorafenib in advanced hepatocellular carcinoma
Josep M. Llovet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Gene expression profiling reveals potential biomarkers of human hepatocellular carcinoma
Hu-Liang Jia et al.
CLINICAL CANCER RESEARCH (2007)
Glypican-3 expression in hepatocellular tumors: diagnostic value for preneoplastic lesions and hepatocellular carcinomas
Xiao Ying Wang et al.
HUMAN PATHOLOGY (2006)
Identification of ROBO1 as a novel hepatocellular carcinoma antigen and a potential therapeutic and diagnostic target
Hirotaka Ito et al.
CLINICAL CANCER RESEARCH (2006)
The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma
N Yamauchi et al.
MODERN PATHOLOGY (2005)
Expression of MUC1 and its significance in hepatocellular and cholangiocarcinoma tissue
Shi-Fang Yuan et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2005)
Glypican-3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt signaling
MI Capurro et al.
CANCER RESEARCH (2005)
Naturally acquired MAGE-A10- and SSX-2-specific CD8+ T cell responses in patients with hepatocellular carcinoma
G Bricard et al.
JOURNAL OF IMMUNOLOGY (2005)
The loss of glypican-3 induces alterations in wnt signaling
HH Song et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Identification of soluble NH2-terminal fragment of glypican-3 as a serological marker for early-stage hepatocellular carcinoma
Y Hippo et al.
CANCER RESEARCH (2004)
Processing by proprotein convertases is required for glypican-3 modulation of cell survival, Wnt signaling, and gastrulation movements
B De Cat et al.
JOURNAL OF CELL BIOLOGY (2003)
Glypican-3: A novel serum and histochemical marker for hepatocellular carcinoma
M Capurro et al.
GASTROENTEROLOGY (2003)
Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker
T Nakatsura et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2003)
Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders
ZW Zhu et al.
GUT (2001)
Developmental roles of the glypicans
B De Cat et al.
SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY (2001)
Expressions of cancer-testis antigens in human hepatocellular carcinomas
CH Chen et al.
CANCER LETTERS (2001)
Molecular cloning and characterization of endosialin, a C-type lectin-like cell surface receptor of tumor endothelium
S Christian et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Glypicans in growth control and cancer
J Filmus
GLYCOBIOLOGY (2001)
Biodegradable polymeric nanoparticles as drug delivery devices
KS Soppimath et al.
JOURNAL OF CONTROLLED RELEASE (2001)
'Stealth' corona-core nanoparticles surface modified by polyethylene glycol (PEG):: influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption
R Gref et al.
COLLOIDS AND SURFACES B-BIOINTERFACES (2000)
Share Paper
